News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

As Johnson & Johnson (JNJ) Closes $30 Billion Deal, Actelion (ALIOF.PK) Spinoff Is Valued at $1.54 Billion In IPO Debut



6/16/2017 6:31:44 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Shares in Idorsia, the drug pipeline firm spun off from biotech group Actelion after Johnson & Johnson's $30 billion takeover, rose nearly 30 percent after making their market debut at 10 Swiss francs each on Friday.

They advanced to nearly 13 francs in early afternoon business in Zurich, valuing the company at above 1.5 billion Swiss francs ($1.54 billion).

One trader said Idorsia's stock had been trading over the counter this week at around 8 francs, the theoretical price given the difference between Actelion's share price in Swiss francs and the $280 cash per share price J&J is paying for Actelion.

Read at Reuters
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES